Vor Biopharma

Robert Ang, CEO

Oct. 10 | 1:45pm | Ecolab Life Sciences Ballroom 

Cambridge, MA

(NASDAQ: VOR)

Vor Bio’s novel approach in the fight against cancer: engineer treatment-resistant Hematopoietic Stem Cells (eHSCs) that allow new, potentially curative targeted therapy opportunities post-transplant. We aim to protect the healthy cells and expose the cancer.

www.vorbio.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions